$ATXG @ .66..$PSIG clone..$ATXG has $3.47

Unlocking the Science of Dietary Bioactives Amidst a world swimming in kale smoothies and exotic teas, ILSI U.S. & Canada gathered the sharpest minds to discuss dietary bioactives, an area once shrugged off but now coming into its own. On October 28, 2026, over 250 folks from government, academia, and industry tuned in, looking to understand how these compounds, found in...

Atlas Ocean Voyages' Grand Plans Anyone who's been sailing this rocky market sea long enough knows there’s no better place to gauge the winds than from a cozy captain's chair—so picture this: Atlas Ocean Voyages just dropped a 2027-28 roadmap that’s more of an atlas in its own right. We’re talking epic voyages spanning Europe, the Med, and Arctic realms, all while...

Markets Stir as NYSE Chair Earns Lifetime Award While the financial world often gets lost in numbers, sometimes it's the people who stand out. NYSE Chair Sharon Bowen is taking the spotlight with her lifetime achievement award, underscoring her game-changing influence in governance. This is more than just a pat on the back; it's a nod to the force she’s been in steering...

A Leap Toward Future Growth You know, not every day does a company manage to turn its early beginnings into a robust franchise system, but Dill Dinkers seems to be onto something here. This pickleball outfit is tossing its original Maryland clubs to local hands, and it’s not just a transaction—it’s a calculated play intending to solidify their expansion path...

Rough Waves for FIS Shareholders If there’s one thing I've learned chewing on greasy bacon over the years, it's that nothing rattles a stock like sketchy numbers and shattered investor confidence. Fidelity National Information Services, or FIS, has just yanked the rug out from its own 2026 forecast, cutting adjusted earnings per share (EPS) to a range of $5.82 to $5.89....

KIR-CAR: A Fresh Take on Cancer Treatment So, Verismo Therapeutics is at it again with their KIR-CAR platform. They're set to present interim data at this year's ASH Annual Meeting. To all those following B-cell non-Hodgkin Lymphoma (B-NHL) treatments, pay attention. SynKIR™-310, a CD19-targeted therapy, is showing some real promise. The science behind this is like...

An Award to Nod At: ASTHO's Public Health Triumph The world of public health isn't generally where you'd find shiny accolades flying around, but when they do, it's worth taking notice. Recently, ASTHO’s podcast, the Public Health Review Morning Edition, snagged a Bronze Anthem Award. Sure, it isn't the gold trophy, but in this high-stakes arena, any medal's a feat! More...

Yealink Sets the Stage for AI Conversations in Munich Ah, the buzz of innovation fills the air once again, as Yealink brings a dizzying array of tech bigwigs together at the Workplace Forward Summit in Munich. This ain't your regular business shindig—this is where the gears of the AI-powered future get some heavy oiling. Imagine 400 industry stalwarts, tech gurus,...

In the churn of Wall Street, every now and then a company's stock ticker takes center stage for all the wrong reasons. The latest contender under the harsh spotlight is none other than D-Wave Quantum Inc. (NASDAQ: QBTS). They're finding themselves marooned in hot water over allegations of securities fraud, which might just send investors scrambling like sand crabs at high...

Crunching the Numbers on Utility Returns There's a buzz in the utility sector, and it's not just the hum of power lines—it’s all about return on equity (ROE). Concentric Energy Advisors just dropped some insights that could have us rethinking how these returns play into customer bills and utilities' financing capabilities. What's the Deal with ROE? Think of ROE like a...

Boldyn Networks Achieves Major Recognition in Private 5G Sector Boldyn Networks, a global leader in private networks and shared communications infrastructure, has made waves in the telecommunications industry with its recent recognition as a Major Player in the IDC MarketScape: European Enterprise Private 5G Solutions 2025 Vendor Assessment. This validation reflects...

LinkSquares: A Game Changer for Contract Management In the world of legal and business operations, few things eat away at patience—let alone profits—like the cumbersome dance of contract management. Enter LinkSquares, strutting onto the stage with its new all-agentic CLM platform, promising to turn this often painful process into a streamlined operation that saves...

Sanctuary Medicinals Shines at NECANN Cup Boston 2025 Sanctuary Medicinals proudly celebrates a remarkable achievement at the 6th Annual NECANN Cup Boston. The company earned the impressive title of 4th place in the competitive Solvent Concentrates category. This accolade showcases Sanctuary Medicinals' unwavering commitment to excellence, innovation, and quality within...

The Growing Challenge of Obesity Drug Coverage For many individuals battling obesity, the struggle is not just about losing weight. It’s also about bearing the financial burden of treatments. With increasing limitations from insurers regarding weight-loss drugs, patients are often forced to alter their lifestyles significantly. Vacations are postponed, dining out is...

Important Attention for Humacyte, Inc. Investors As an investor in Humacyte, Inc., it’s essential to stay informed about legal opportunities that could impact your investments. The Rosen Law Firm, known for its dedication to protecting investor rights, is reminding those who purchased Humacyte securities during a specified period about an important upcoming deadline....